收费全文 | 240345篇 |
免费 | 38951篇 |
国内免费 | 8598篇 |
医药卫生 | 287894篇 |
2024年 | 977篇 |
2023年 | 5818篇 |
2022年 | 4156篇 |
2021年 | 6696篇 |
2020年 | 8976篇 |
2019年 | 4624篇 |
2018年 | 9675篇 |
2017年 | 10013篇 |
2016年 | 10640篇 |
2015年 | 12234篇 |
2014年 | 20271篇 |
2013年 | 20270篇 |
2012年 | 12735篇 |
2011年 | 13281篇 |
2010年 | 16315篇 |
2009年 | 19504篇 |
2008年 | 11645篇 |
2007年 | 9853篇 |
2006年 | 12117篇 |
2005年 | 9029篇 |
2004年 | 6542篇 |
2003年 | 5089篇 |
2002年 | 4683篇 |
2001年 | 5879篇 |
2000年 | 4769篇 |
1999年 | 4770篇 |
1998年 | 4663篇 |
1997年 | 4445篇 |
1996年 | 4078篇 |
1995年 | 3853篇 |
1994年 | 2527篇 |
1993年 | 1929篇 |
1992年 | 1723篇 |
1991年 | 1712篇 |
1990年 | 1327篇 |
1989年 | 1367篇 |
1988年 | 1202篇 |
1987年 | 1004篇 |
1986年 | 1015篇 |
1985年 | 799篇 |
1984年 | 578篇 |
1983年 | 546篇 |
1982年 | 529篇 |
1981年 | 421篇 |
1980年 | 370篇 |
1979年 | 317篇 |
1978年 | 330篇 |
1977年 | 397篇 |
1975年 | 277篇 |
1972年 | 305篇 |
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
Robotic approaches have been steadily replacing laparoscopic approaches in metabolic and bariatric surgeries (MBS); however, their superiority has not been rigorously evaluated. The main goal of the study was to evaluate the 5-year utilization trends of robotic MBS and to compare to laparoscopic outcomes.
MethodsRetrospective analysis of 2015–2019 MBSAQIP data. Kruskal-Wallis test/Wilcoxon and Fisher’s exact/chi-square were used to compare continuous and categorical variables, respectively. Generalized linear models were used to compare surgery outcomes.
ResultsThe use of robotic MBS increased from 6.2% in 2015 to 13.5% in 2019 (N= 775,258). Robotic MBS patients had significantly higher age, BMI, and likelihood of 12 diseases compared to laparoscopic patients. After adjustment, robotic MBS patients showed higher 30-day interventions and 30-day readmissions alongside longer surgery time (26–38 min).
ConclusionRobotic MBS shows higher intervention and readmission even after controlling for cofounding variables.
Graphical Abstract 相似文献